- Home
- IVT vs NRIX Comparison
IVT vs NRIX Comparison
Compare IVT & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IVT | NRIX |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IVT | NRIX |
|---|---|---|
| Price | $29.75 | $22.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 14 |
| Target Price | ★ $36.63 | $33.93 |
| AVG Volume (30 Days) | 588.4K | ★ 1.2M |
| Earning Date | 10-27-2026 | 10-20-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | ★ 647.37 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $299,169,000.00 | $76,987,000.00 |
| Revenue This Year | $12.14 | $799.42 |
| Revenue Next Year | $6.97 | N/A |
| P/E Ratio | $372.50 | ★ N/A |
| Revenue Growth | 9.20 | ★ 99.31 |
| 52 Week Low | $26.81 | $9.00 |
| 52 Week High | $37.22 | $28.23 |
Technical Indicators
Market Signals| Indicator | IVT | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 23.49 | 32.74 |
| Support Level | $28.51 | $21.23 |
| Resistance Level | $31.71 | $24.98 |
| Average True Range (ATR) | 0.55 | 0.88 |
| MACD | -0.02 | -0.23 |
| Stochastic Oscillator | 5.61 | 9.41 |
Price Performance
Historical ComparisonAbout IVT InvenTrust Properties Corp.
InvenTrust Properties Corp is the United States of America based company qualified as a REIT (Real Estate Investment Trust). It is focused on owning, leasing, redeveloping, acquiring and managing a multi-tenant retail platform. The company's wholly-owned and managed retail properties include grocery-anchored community and neighborhood centers and power centers, including those classified as necessity-based. InvenTrust operates through a single segment i.e. multi-tenant retail.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.